A new way to prevent HIV infection is generating great buzz -- and more than a bit of controversy -- at this week’s AIDS 2024 Conference in Munich.

The treatment consists of a twice-yearly injection of a drug called lenacapavir.

Early trial results were released in June and generated great excitement, indicating 100% efficacy. On Wednesday, July 24, the full peer-reviewed results were released at the AIDS 2024 conference, confirming the preliminary data.

The trial was sponsored by Gilead Sciences, the California-based maker of the drug.

This treatment offers an alternative to the current standard of core for HIV prevention efforts for over a decade: taking a pill like Truvada every day.